Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Companyâ€™s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/10/26	SEK 3.530	-1.12%	163,366
01/10/26	SEK 3.570	+5.00%	577,486
30/09/26	SEK 3.400	+3.03%	447,904
29/09/26	SEK 3.300	+5.77%	574,593
28/09/26	SEK 3.120	+2.30%	141,219

Delayed Quote Nasdaq Stockholm

More quotes

Net sales - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 17:00:00 02/10/2026 BST			5-day change	1st Jan Change
3.530 ^SEK	-1.12%		+15.74%	+140.14%

08-26	Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-23	Sprint Bioscience AB and Eli Lilly and Company Enter Agreement to Accelerate Drug Development	CI

Market Cap	372M 37.11M 32.98M 30.78M 28.05M 52.91M 3.57B 53.4M 144M 1.82B 139M 136M 5.85B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	372M 37.11M 32.98M 30.78M 28.05M 52.91M 3.57B 53.4M 144M 1.82B 139M 136M 5.85B	EV / Sales 2026 *	4.29x	EV / Sales 2027 *	3.85x
Free-Float	72.16%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	SPRINT	Delayed
Deutsche Boerse AG	5JA1	Delayed
Börse Stuttgart	5JA1	Delayed
Boerse Muenchen	5JA1	Real-time

08-26	Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-23	Sprint Bioscience AB and Eli Lilly and Company Enter Agreement to Accelerate Drug Development	CI
06-26	Four stocks have so far today posted new 52-week highs on the Stockholm Stock Exchange	FW
06-18	Nine stocks hit new 52-week highs on the Stockholm Stock Exchange today	FW
06-16	Three stocks hit new 52-week highs on the Stockholm Stock Exchange today	FW
06-09	Calendar: Tuesday, June 9	FW
06-08	Calendar Tuesday June 9	FW
05-13	Sprint Bioscience Q1 operating loss SEK 14.3 mln	RE
05-13	Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-16	Sprint Bioscience completes strategic evaluation of STK25 program	RE
04-16	Sprint Bioscience and Experimental Drug Development Centre Complete Strategic STK25 Evaluation	CI
04-14	21 stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW
04-10	15 stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW

Sprint Bioscience AB Share Price

Stocks

SPRINT

SE0006343745

Biotechnology & Medical Research

Valuation: Sprint Bioscience AB

Chart: Sprint Bioscience AB

Latest news: Sprint Bioscience AB

Analysts' recommendations: Sprint Bioscience AB

Press Releases: Sprint Bioscience AB

Quotes and Performance

Price Extremes

Managers and Directors: Sprint Bioscience AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

10-02	Sprint Bioscience: Vinnova funding for fragment screening project	AQ
10-01	Sprint Bioscience Receives Funding from Vinnova	AQ
09-02	Sprint Bioscience (Q2 review): Continued positive progress	AQ
08-13	Sprint Bioscience's Upcoming Conferences and Investor Events	AQ
07-23	Sprint Bioscience announces agreement with Lilly TuneLab to accelerate drug development	AQ

1 day	-1.12%
1 week	+15.74%
Current month	+3.82%
1 month	+7.62%
3 months	-13.05%
6 months	+41.20%
Current year	+140.14%

1 week	2.96	3.57
1 month	2.55	3.57
Current year	1.36	4.59
1 year	0.57	4.59
3 years	0.36	4.59
5 years	0.36	5.4
10 years	0.36	40.7

Manager	Title	Age	Since
Johan Emilsson CEO	Chief Executive Officer	42	30/09/2023
Martin Andersson CTO	Chief Tech/Sci/R&D Officer	55	31/12/2008
Jenni Björnulfson DFI	Director of Finance/CFO	55	03/05/2026

Director	Title	Age	Since
Nils Rune Nordlander CHM	Chairman	70	31/12/2009
Fredrik Lehmann BRD	Director/Board Member	50	31/12/2018
Björn Magnus Sjöstrand CHM	Chairman	58	31/12/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPRINT BIOSCIENCE AB	-1.12%	+15.74%	+512.85%	+73.04%	37.11M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+21.92%	+74.60%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+4.28%	+34.51%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+352.17%	+689.61%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+26.36%	+33.18%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+3.74%	+100.60%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.63%	+19.50%	28.53B
BIONTECH SE	+0.05%	-1.64%	-7.28%	-14.06%	24.34B
Average	-0.32%	+1.05%	+100.23%	+115.56%	39.06B
Weighted average by Cap.	+0.12%	-0.84%	+58.81%	+129.90%

	2026 *	2027 *
Net sales	86.8M 8.65M 7.68M 7.17M 6.54M 12.33M 831M 12.44M 33.64M 425M 32.47M 31.77M 1.36B	96.8M 9.65M 8.57M 8M 7.29M 13.75M 927M 13.88M 37.51M 474M 36.21M 35.43M 1.52B
Net income	-	-
Net Debt	-	-